Dr Trevisan is a neurophysiologist with a wide experience in the field of human physiology and medical devices. He has worked on international research projects in England and France and has given presentations at international conferences and congress, as well as holding a visiting lecturing post at the University of Malta and delivering presentations at the Università degli Studi di Milano. Dr Trevisan has benefited from research grants and formed part of research projects under a number of EU and local funding programmes.
Dr Adrian Trevisan was integral in the founding of Neurotech and has since retired in 2018. He was also the founder, chief executive and chief scientific officer of AAT Research, a group of companies involved in the development of certified medical devices. The company has since rebranded itself as Neurotech International, becoming a public listed company on the Australian Securities Exchange (ASX), and he remained as a non-executive director until June 2018. He is a co-founder and chief executive of Umana Medical Technologies, a developer and manufacturer of patented temporary tattoo sensors that enable patients and medical professionals to monitor vital signs of patients, without the usual restrictions of cables and wires that affect quality of life.
Dr Trevisan is a research fellow of the Bedfordshire Center for Mental Health Research in association with the University of Cambridge.